细胞因子释放综合征与COVID-19免疫治疗的前景。第2部分：白细胞介素1的作用。
Cytokine release syndrome and the prospects for immunotherapy with COVID-19. Part 2: The role of interleukin 1.
作者信息
Calabrese Leonard H, Calabrese Cassandra
机构信息
Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute, Cleveland Clinic; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute, and Department of Infectious Disease, Cleveland Clinic.
出版信息
Cleve Clin J Med. 2020 Jul 9. doi: 10.3949/ccjm.87a.ccc044.
Interleukin 1 (IL-1) is a potential target of therapy in COVID-19 during the severe respiratory-inflammatory phase ("cytokine release syndrome"), when pulmonary macrophages are hyperactivated, releasing IL-1 and other cytokines. Preliminary evidence indicates that anakinra and canakinumab, drugs that block the action of IL-1 and have a good safety profile, improve the outcomes of patients with COVID-19 cytokine release syndrome. Results from large, randomized clinical trials are pending.
白细胞介素1（IL-1）是新冠病毒疾病（COVID-19）严重呼吸炎症阶段（“细胞因子释放综合征”）的潜在治疗靶点，在此阶段肺巨噬细胞过度活化，释放IL-1和其他细胞因子。初步证据表明，阿那白滞素和卡那单抗这两种可阻断IL-1作用且安全性良好的药物，可改善新冠病毒疾病细胞因子释放综合征患者的预后。大型随机临床试验的结果尚未得出。
Zotero 插件